Q4 2023 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2024-02-14 · accession 0001214659-24-002827
$625.0M
Reported value
33
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $168.0M | 26.9% | 2,806,980 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $63.2M | 10.1% | 2,673,750 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $47.1M | 7.54% | 2,369,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $39.8M | 6.37% | 1,284,000 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $35.7M | 5.71% | 1,868,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $28.5M | 4.57% | 706,800 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $28.1M | 4.49% | 707,526 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $28.0M | 4.48% | 2,494,000 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $23.7M | 3.79% | 1,241,300 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $16.9M | 2.70% | 414,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $16.4M | 2.62% | 2,060,100 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $13.6M | 2.18% | 664,575 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $13.5M | 2.16% | 620,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $11.5M | 1.84% | 273,289 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $10.5M | 1.69% | 792,945 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $9.7M | 1.55% | 116,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $9.3M | 1.49% | 2,050,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $9.1M | 1.46% | 403,685 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $8.4M | 1.34% | 9,187,883 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $7.3M | 1.16% | 292,000 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $7.1M | 1.13% | 3,000,000 | Common | SOLE |
| 38406L103 | — | GRACELL BIOTECHNOLOGIES INC | $6.0M | 0.96% | 596,611 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $5.8M | 0.92% | 554,000 | Common | SOLE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $3.6M | 0.58% | 2,250,000 | Common | SOLE |
| 471871103 | — | JASPER THERAPEUTICS INC | $3.5M | 0.56% | 4,468,114 | Common | SOLE |
| 92536C103 | VERUEUR | VERU INC | $2.7M | 0.44% | 3,800,000 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $2.6M | 0.41% | 120,000 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $1.7M | 0.27% | 400,000 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $1.5M | 0.24% | 1,000,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $981,750 | 0.16% | 1,785,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $738,000 | 0.12% | 25,000 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $456,500 | 0.07% | 50,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $105,000 | 0.02% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.